Cargando…

P664: REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS

Detalles Bibliográficos
Autores principales:	Hu, Shiwei, Wu, Dijiong, Feng, Weiying, Chen, Lili, Cao, Lihong, Zhu, Xiaoqiong, Yang, Xiudi, Zhu, Jingjing, Wang, Huafeng, Chen, Dan, Tong, Hongyan, Lu, Ying, Qian, Honglan, Wang, Yi, Jin, Jie, Huang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428900/ http://dx.doi.org/10.1097/01.HS9.0000969560.77193.a9

Ejemplares similares

Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
por: Hu, Shiwei, et al.
Publicado: (2022)

P684: A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS
por: Huang, Jian, et al.
Publicado: (2023)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
por: Catalano, Gianfranco, et al.
Publicado: (2020)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Terasawa, Teruhiko, et al.
Publicado: (2011)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
por: Tadesse, Fisihatsion, et al.
Publicado: (2021)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
por: Gao, Congying, et al.
Publicado: (2023)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
por: Chandrasekhar, Chodimella, et al.
Publicado: (2019)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
por: Jiang, Liang, et al.
Publicado: (2021)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A
por: Xu, Yun, et al.
Publicado: (2023)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
por: Leder, Kevin, et al.
Publicado: (2011)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case
por: Al-Achkar, Walid, et al.
Publicado: (2014)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
por: Limsuwanachot, Nittaya, et al.
Publicado: (2023)

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2023)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
por: Huang, Xianbo, et al.
Publicado: (2019)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
por: Bang, Soo-Mee, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0ph6o650me2qqu9u55po14v6sv